Sei Investments Co. Buys 153,006 Shares of Enovis Co. (NYSE:ENOV)

Sei Investments Co. increased its stake in shares of Enovis Co. (NYSE:ENOV) by 51.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 453,241 shares of the company’s stock after buying an additional 153,006 shares during the quarter. Sei Investments Co. owned 0.80% of Enovis worth $19,888,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. UMB Bank n.a. raised its stake in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock worth $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock worth $37,000 after purchasing an additional 300 shares in the last quarter. FMR LLC lifted its holdings in Enovis by 20.5% during the 3rd quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares during the last quarter. XTX Topco Ltd acquired a new position in Enovis in the third quarter valued at about $217,000. Finally, Legacy Capital Wealth Partners LLC bought a new stake in Enovis during the fourth quarter worth about $228,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Trading Down 0.8 %

Shares of NYSE ENOV opened at $38.89 on Friday. Enovis Co. has a 1-year low of $35.14 and a 1-year high of $62.79. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a 50-day moving average of $42.24 and a two-hundred day moving average of $43.38. The company has a market cap of $2.22 billion, a PE ratio of -17.76 and a beta of 2.05.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. As a group, equities analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reduced their target price on Enovis from $65.00 to $64.00 and set a “buy” rating on the stock in a report on Thursday, February 27th.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.